Abstracts tagged "pregnancy"

Abstract Number: 1775 • ACR Convergence 2020
Risk Factors for Adverse Pregnancy Outcomes of Women with Positive for Antiphospholipid Antibodies Treated with Conventional Therapies
Hiromi Shimada¹, Risa Wakiya², Mai Mahmound Fahmy Mansour¹, Shusaku Nakashima¹, Mikiya Kato¹, Koichi Sugihara¹, Yusuke Ushio¹, Tomohiro Kameda¹ and Hiroaki Dobashi³, ¹Department of Internal Medicine, Division of Haematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University., Kita-gun, Kagawa, Japan, ²Department of Internal Medicine, Division of Haematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University., Kagawa, Kagawa, Japan, ³Department of Internal Medicine, Division of Haematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan
Background/Purpose: Antiphospholipid antibodies induce several obstetric complications including recurrent spontaneous abortion, preterm birth, intrauterine fetal death. EULAR recommendations for antiphospholipid syndrome (APS) indicates low dose…
Abstract Number: 0033 • ACR Convergence 2020
Pre-pregnancy Long Non-coding RNA Expression Signatures Among Women with Rheumatoid Arthritis Who Improve or Worsen During Pregnancy
Matthew Wright¹, Mette Kiel Smed², J Lee Nelson³, Jørn Olsen⁴, Merete Hetland⁵, Vibeke Zoffmann² and Damini Jawaheer⁶, ¹UCSF Children's Hospital Oakland Research Institute, Oakland, CA, ²The Juliane Marie Center, Copenhagen, Denmark, ³Fred Hutchinson Cancer Res Ctr and U of WA, Seattle, WA, ⁴Aarhus University Hospital, Aarhus, Denmark, ⁵The DANBIO Registry, Rigshospitalet, Glostrup, Denmark, ⁶UCSF Benioff Children's Hospital Oakland Research Institute, Oakland, CA
Background/Purpose: Pregnancy is known to have disease-modifying effects on rheumatoid arthritis (RA). A role for long non-coding (lnc) RNAs in the improvement or worsening of…
Abstract Number: 1497 • ACR Convergence 2020
COVID-19 in Pregnant Patients with Rheumatic Disease: Data from the COVID-19 Global Rheumatology Alliance
Bonnie Bermas¹, Megan Clowse², Milena Gianfrancesco³, Jonathan Hausmann⁴, Pedro M Machado⁵, Emily Sirotich⁶, Helen Robinson⁷, Anja Strangfeld⁸, Jinoos Yazdany⁹ and Philip Robinson¹⁰, ¹UTSouthwestern.edu, Dallas, TX, ²Duke University, Chapel Hill, NC, ³University of California, San Francisco, San Francisco, CA, ⁴Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ⁵University College London, London, United Kingdom, ⁶McMaster University, Hamilton, ON, Canada, ⁷University of Queensland School of Medicine, HERSTON, Queensland, Australia, ⁸German Rheumatism Research Center, Berlin, Germany, ⁹UCSF, San Francisco, CA, ¹⁰University of Queensland, Herston, Queensland, Australia
Background/Purpose: The impact of COVID-19 on pregnancy in patients with rheumatic disease is unknown. We describe COVID-19 outcomes in pregnant rheumatic disease patients reported to…
Abstract Number: 1776 • ACR Convergence 2020
Safety and Beneficial Effects of Hydroxychloroquine on Pregnancy Outcomes in Women with Systemic Lupus Erythematosus
Isabell Haase¹, Matthias Schneider¹, Ralph Brinks¹ and Rebecca Fischer-Betz¹, ¹Department of Rheumatology and Hiller Research Unit Rheumatology, Heinrich Heine University, Duesseldorf, Germany, Duesseldorf, Germany
Background/Purpose: The use of hydroxychloroquine (HCQ) has long been established in Systemic Lupus Erythematosus(SLE) and especially as applicable drug during pregnancy. Recently, beneficial effects and…
Abstract Number: 0238 • ACR Convergence 2020
Gestational Desire and Certolizumab Pegol in Patients with Chronic Inflammatory Rheumatic Disease. Preliminary Results of the GESTAMAD Cohort
Laura Gonzalez Hombrado¹, Marina Salido Olivares², Maria Carmen Ortega de la O³, Pilar Navarro Alonso⁴, Patricia Castro Perez⁵, Ana Castilla⁶, Alvaro Garcia Martos⁷, Celia Arconada³, Angel Aragon Diez⁸, Carolina Marin huertas³ and Eva Maria Andres Esteban⁹, ¹Hospital Universitario del Tajo, MADRID, Spain, ²Hospital de Parla, Madrid, Spain, ³Hospital infanta Elena, Madrid, Spain, ⁴Hospital de Fuenlabrada, Madrid, Madrid, Spain, ⁵Hospital Universitario de Getafe, Madrid, Spain, ⁶Hospital Universitario La Paz, Madrid, Spain, ⁷Hospital Universitario del Tajo, Madrid, ⁸Hospital Universitario de Gerafe, Madrid, Spain, ⁹Rey Juan Carlos University, Madrid, Spain
Background/Purpose: INTRODUCTION The use of biological therapies during pregnancy has been contraindicated since the beginning of the use of these drugs. In recent years several…
Abstract Number: 1498 • ACR Convergence 2020
Pregnancy Outcomes in Patients with Axial Spondyloarthritis – a First Analysis of a European Collaboration of Pregnancy Registries
Yvette Meissner¹, Nathalie Costedoat-Chalumeau², Frauke Foerger³, Doreen Goll⁴, Anna Molto⁵, Rebecca Özdemir⁶, Marianne Wallenius⁷, Anja Strangfeld⁸ and Rebecca Fischer-Betz⁹, ¹Deutsches Rheuma-Forschungszentrum, Berlin, Germany, ²APHP, Université de Paris, Paris, France, ³University Hospital and University of Bern, Bern, Switzerland, Bern, Switzerland, ⁴Patient Research Partner, Berlin, Germany, ⁵Rheumatology Department, Cochin Hospital, Paris, Paris, France, ⁶Patient Research Partner, Duisburg, Germany, ⁷University Hospital and Norwegian University of Science and Technology, Trondheim, Norway, ⁸German Rheumatism Research Center, Berlin, Germany, ⁹Department of Rheumatology and Hiller Research Unit Rheumatology, Heinrich Heine University, Duesseldorf, Germany, Duesseldorf, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) can affect women in their childbearing age. Data on pregnancy in axSpA patients are mainly retrospective and highly heterogeneous [1]. The…
Abstract Number: 1777 • ACR Convergence 2020
Low Dose Aspirin to Prevent Pre-eclampsia in SLE Pregnancies – Counselling Helps to Realize Our Full Potential
Isabell Haase¹, Matthias Schneider¹, Ralph Brinks¹ and Rebecca Fischer-Betz¹, ¹Department of Rheumatology and Hiller Research Unit Rheumatology, Heinrich Heine University, Duesseldorf, Germany, Duesseldorf, Germany
Background/Purpose: Women with Systemic Lupus Erythematosus (SLE) face a higher risk of pre-eclampsia, especially those with additional risk factors. Low dose aspirin (LDA) is known…
Abstract Number: 1896 • 2019 ACR/ARP Annual Meeting
Breastfeeding in Women with Rheumatic Diseases
Naira Ikram¹, Amanda Eudy ¹ and Megan Clowse ¹, ¹Duke University, Durham
Background/Purpose: For many women, breastfeeding is a central aspect of motherhood, but many worry that their rheumatic disease or treatment will interfere. Fortunately, most anti-rheumatic…
Abstract Number: 1899 • 2019 ACR/ARP Annual Meeting
sFlt-1, PlGF and VEGF in the Differential Diagnosis Between Active SLE Nephritis During Pregnancy and Preeclampsia
Guilherme De Jesus¹, Marcela Lacerda ¹, Bruna Rodrigues ¹, Flavia dos Santos ¹, Adriana Nascimento ¹, Luis Cristóvão Porto ¹, Nilson Ramires de Jesús ¹, Roger Levy ² and Evandro Klumb ¹, ¹Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²GlaxoSmithKline, Upper Providence, PA
Background/Purpose: Pregnancy in patients with SLE is associated with significant morbidity and mortality. SLE activity during pregnancy, specifically nephritis, makes the differential diagnosis with preeclampsia…
Abstract Number: 1900 • 2019 ACR/ARP Annual Meeting
Assessing Commercial Titers of anti-Ro60 and Ro52 Antibodies to Risk Stratify Surveillance of Anti-Ro/SSA Antibody Positive Pregnancies
Kimberly Robins ¹, Rohit Bhan¹, Catherine Trad ¹, Rebecca Cohen ¹, Miao Chang ¹, Benjamin Wainwright ¹, Mala Masson ¹, Shilpi Mehta-Lee ¹, Peter Izmirly ¹, Robert Clancy ¹, Bettina Cuneo ² and Jill Buyon ¹, ¹NYU School of Medicine, New York, ²Children's Hospital Colorado, Aurora
Background/Purpose: Pregnancy counseling of all anti-Ro positive women includes advice regarding the development of congenital heart block (CHB), albeit the risk is only 2% for…
Abstract Number: 1901 • 2019 ACR/ARP Annual Meeting
Serious Infections in Offspring Exposed in Utero to Non-TNFi Biologics and Tofacitinib
Evelyne Vinet¹, Yvan St-Pierre ¹, Cristiano S. Moura ¹, Jeffrey Curtis ² and Sasha Bernatsky ³, ¹McGill University Health Centre, Montreal, QC, Canada, ²University of Alabama at Birmingham, Birmingham, AL, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: During pregnancy, maternal circulating immunoglobulins G (IgG) are actively transported across the placenta through their Fc portion. Thus, TNFi and other biologics harbouring an Fc…
Abstract Number: 1938 • 2019 ACR/ARP Annual Meeting
The Pre-pregnancy Rheumatoid Arthritis Gene Expression Signature Correlates with Improvement or Worsening of Disease Activity During Pregnancy: A Pilot Study
Amogh Pathi ¹, Mette Smed ², Lior Pachter ³, Elizabeth Purdom ⁴, Matthew Wright ⁵, Nicholas Jewell ⁴, J. Lee Nelson ⁶, Jørn Olsen ⁷, Merete Lund Hetland ⁸, Vibeke Zoffmann ⁹ and Damini Jawaheer¹⁰, ¹UCSF Benioff Children's Hospital Oakland, Oakland, ²Juliane Marie Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ³Caltech, Pasadena, ⁴University of California Berkeley, Berkeley, ⁵UCSF Benioff Children's Hopsital Oakland, Oakland, ⁶Fred Hutchinson Cancer Research Center, Seattle, ⁷Aarhus University Hospital, Aarhus, Denmark, ⁸DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ⁹Juliane Marie Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, ¹⁰UCSF Benioff Children's Hospital Oakland, Oakland, CA
Background/Purpose: Pregnancy is known to induce a natural improvement of Rheumatoid Arthritis (RA) symptoms in 50-75% of patients as gestation progresses. However, the underlying mechanisms…
Abstract Number: 2273 • 2019 ACR/ARP Annual Meeting
Risk of Serious Infections in Offspring According to TNFi Subtypes
Evelyne Vinet¹, Yvan St-Pierre ¹, Cristiano S. Moura ¹, Jeffrey Curtis ² and Sasha Bernatsky ³, ¹McGill University Health Centre, Montreal, QC, Canada, ²University of Alabama at Birmingham, Birmingham, AL, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: TNFi subtypes have differential placental transfer, with some reaching higher fetal than maternal blood levels. Thus, certain TNFi subtypes could cause immunosuppression in the offspring.…
Abstract Number: 2276 • 2019 ACR/ARP Annual Meeting
Impact of the Healthy Outcomes in Pregnancy with SLE Through Education of Providers (HOP-STEP) Program: A Mixed Methods Approach
Ravyn Njagu¹, Amanda Eudy ², Amanda Snyderman ¹, Lisa Criscione-Schreiber ² and Megan Clowse ², ¹Duke University, Durham, NC, ²Duke University, Durham
Background/Purpose: While centers have worked to optimize lupus pregnancy outcomes, additional efforts are required to have a broader impact on lupus pregnancy outcomes. The goal…
Abstract Number: 2277 • 2019 ACR/ARP Annual Meeting
Perspectives of Female Patients with Rheumatic Diseases Regarding Pregnancy Planning with Rheumatologists
Tierney Wolgemuth ¹, Mehret Birru Talabi ¹, Alaina Chodoff ², Sonya Borrero ³ and Mehret Talabi¹, ¹University of Pittsburgh, Pittsburgh, PA, ²UPMC, Pittsburgh, ³University of Pittsburgh, Pittsburgh
Background/Purpose: Women with rheumatic diseases may be at greater risk for adverse maternal, perinatal, and pregnancy outcomes. The American College of Rheumatology recommends that female…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].